1.. INTRODUCTION
================

Colorectal cancer includes cancers of both the colon and the rectum, and is the most common form of gastrointestinal cancer. In Canada, colorectal cancer is the fourth most common cancer in terms of incidence rates, both sexes combined, and second only to lung cancer as a cause of cancer death [@b1-conc17-1-17]. With estimated age-standardized incidence rates for 2009 of 62 and 41 per 100,000 for men and women respectively, colorectal cancer is expected to develop in 1 in every 14 men and 1 in every 16 women during their lifetime, with 1 in 27 men and 1 in 31 women dying from the disease [@b1-conc17-1-17]. In 2009, an estimated 22,000 Canadians will be diagnosed with colorectal cancer, and 9100 will die [@b1-conc17-1-17]. A recent Canadian analysis [@b2-conc17-1-17] noted that any modest decreases in incidence and mortality rates are more than offset by the increasing numbers of new cases attributable to the aging population. There is thus no sign of the burden of colorectal cancer abating. With so many at risk, effective treatments for colon cancer are critical.

In 2007, based on results of the [mosaic]{.smallcaps} (Multi-center International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study, Health Canada approved oxaliplatin (Eloxatin: Sanofi--Aventis Canada Inc., Laval, QC) in combination with 5-fluorouracil/leucovorin (5[fu]{.smallcaps}/[lv]{.smallcaps}) as adjuvant treatment in patients with stage [iii]{.smallcaps} colon cancer.

In [mosaic]{.smallcaps}, a large international randomized phase [iii]{.smallcaps} trial (146 centres), the [folfox]{.smallcaps}4 regimen (oxaliplatin/5[fu]{.smallcaps}/[lv]{.smallcaps}, hereinafter "[folfox]{.smallcaps}") was compared with [5fu]{.smallcaps}/[lv]{.smallcaps} alone in patients with stage [ii]{.smallcaps} or [iii]{.smallcaps} colon cancer [@b3-conc17-1-17]. At a median follow-up of 3 years, the addition of oxaliplatin reduced the risk of recurrence by 23% in stage [ii]{.smallcaps} and [iii]{.smallcaps} patients who had undergone surgery for their primary tumour and by 24% in the subset of stage [iii]{.smallcaps} patients. After 77 months of follow-up, this benefit in stage [iii]{.smallcaps} patients was confirmed at the 5-year mark (22% risk reduction in relapse or disease recurrence) [@b4-conc17-1-17]. At a median follow-up of 6 years, a 20% reduction in risk of death was observed in stage [iii]{.smallcaps} colon cancer patients [@b5-conc17-1-17]. Furthermore, as of the January 2007 cut-off update, significant benefits in overall survival ([os]{.smallcaps}) were also seen in the intention-to-treat ([itt]{.smallcaps}) population [@b5-conc17-1-17]. These results support [folfox]{.smallcaps} as the current standard for adjuvant therapy in colon cancer [@b6-conc17-1-17]. In fact, based on a review of colon cancer patient charts conducted for cases resected in 2007--2008 for Cancer Care Ontario ([cco]{.smallcaps}), [folfox]{.smallcaps} was the chemotherapy agent most commonly used in Ontario, with 78.6% of patients treated outside of clinical trials receiving this regimen [@b7-conc17-1-17].

Currently, [folfox]{.smallcaps} is reimbursed for stage [iii]{.smallcaps} colon cancer in all Canadian provinces. Ontario and British Columbia further reimburse it in high-risk stage [ii]{.smallcaps} colon cancer and in rectal cancer. Decisions to fund are based on not only the clinical benefit of a product, but also whether the product provides reasonable value in terms of clinical benefit for the cost of treatment. The cost--utility analysis ([cua]{.smallcaps}) presented here was conducted to determine the value---in terms of the incremental costs per life-year ([ly]{.smallcaps}) gained and per quality-adjusted life-year ([qaly]{.smallcaps}) gained---of oxaliplatin as used in the [folfox]{.smallcaps} regimen, compared with infusional 5[fu]{.smallcaps}/[lv]{.smallcaps} alone, for the adjuvant therapy of patients with completely resected stage [iii]{.smallcaps} (Dukes C) colon cancer. In October 2008 in Ontario, the recommendations of the Committee to Evaluate Drugs to fund oxaliplatin were based, in part, on the results reported here [@b6-conc17-1-17].

2.. METHODS
===========

2.1. Study Design
-----------------

The [cua]{.smallcaps} compared oxaliplatin in combination with 5[fu]{.smallcaps}/[lv]{.smallcaps} administered per the [folfox]{.smallcaps}4 regimen against 5[fu]{.smallcaps}/[lv]{.smallcaps} alone, using data at the level of the individual patient from the previously reported [mosaic]{.smallcaps} trial [@b3-conc17-1-17]. The [mosaic]{.smallcaps} phase [iii]{.smallcaps} trial included 2246 patients with stage [ii]{.smallcaps} (40%) and [iii]{.smallcaps} (60%) colon cancer whose tumours had been completely surgically removed. The primary trial endpoint was disease-free survival ([dfs]{.smallcaps}) at 3 years. Secondary trial endpoints included toxicity and [os]{.smallcaps}. Outcomes were analyzed based on the [itt]{.smallcaps} population. Patients were randomized to receive 5[fu]{.smallcaps}/[lv]{.smallcaps} or [folfox]{.smallcaps} every 2 weeks for 12 cycles as defined in the [mosaic]{.smallcaps} trial and recommended by [cco]{.smallcaps} guidelines [@b8-conc17-1-17].

For several reasons, including the fact that randomized trials are typically of short duration, [cuas]{.smallcaps} often combine data taken from randomized trials with the use of decision analytic modelling. Similarly, the present analysis derived estimates of clinical effectiveness ([dfs]{.smallcaps} and [os]{.smallcaps}) and resource use from the [mosaic]{.smallcaps} trial and extrapolated the clinical benefits and costs specific to each regimen over the lifetime (50 years) of the patient cohort.

The primary outcome measure chosen for this economic evaluation was the [qaly]{.smallcaps}; however, disease-free years ([dfys]{.smallcaps}) and [lys]{.smallcaps} gained are also reported. The [qaly]{.smallcaps} reflects [os]{.smallcaps}, adjusted by health-related quality of life. To calculate [qalys]{.smallcaps}, life-years are multiplied by utility values that represent preference-based values for health states. Utility values vary depending on age, sex, and the occurrence of relapse or adverse events. Because utility values were not collected in the [mosaic]{.smallcaps} trial, these estimates were derived from the available literature.

The analysis included disease-related health care costs from the perspective of the Ontario Ministry of Health and Long-Term Care. Resource utilization data were derived from the [mosaic]{.smallcaps} trial, and unit costs were derived from the Ontario Ministry of Health and Long-Term Care, the London Health Sciences Centre, and the published literature. Costs and outcomes were discounted to present values at a rate of 5% per year [@b9-conc17-1-17].

To test the robustness of the base-case results to variations in input parameters and assumptions, one-way sensitivity analyses were performed on discount rates, utility values, the choice of time horizon, and patient population (stages [ii]{.smallcaps} and [iii]{.smallcaps}).

2.2. Patient Population
-----------------------

The inclusion criteria for patients in the [mosaic]{.smallcaps} trial have been published [@b3-conc17-1-17]. To summarize, patients were between 18 and 75 years of age and had undergone complete surgical resection of histologically proven stage [ii]{.smallcaps} (T3 or T4, N0, M0) or stage [iii]{.smallcaps} (any T, N1 or N2, M0) colon cancer. For our base case analysis, only patients with stage [iii]{.smallcaps} colon cancer were considered.

2.3. Treatment Regimens
-----------------------

Treatment commenced no later than 7 weeks post surgery. Patients were randomized to these treatment groups:

-   5[fu]{.smallcaps}/[lv]{.smallcaps} group: (given on both days 1 and 2 every 14 days for 12 cycles) a 2-hour infusion of [lv]{.smallcaps} 200 mg/m^2^, followed by a bolus of 5[fu]{.smallcaps} 400 mg/m^2^, followed by a 22-hour protracted infusion of 5[fu]{.smallcaps} 600 mg/m^2^

-   [folfox]{.smallcaps} group: exactly the same as for the 5[fu]{.smallcaps}/[lv]{.smallcaps} group, except that a 2-hour infusion of oxaliplatin 85 mg/m2 is given simultaneously with the 2-hour infusion of [lv]{.smallcaps} 200 mg/m2 on day 1 only

2.4. Effectiveness Assessment
-----------------------------

Treatment effectiveness was summarized in terms of [qalys]{.smallcaps} so as to capture survival as well as health-related quality of life.

### 2.4.1. Survival

The primary endpoint of the [mosaic]{.smallcaps} trial was [dfs]{.smallcaps}. The median period of follow-up in that trial was 44.2 months at the time that the present economic evaluation was developed. Patient-level data regarding [os]{.smallcaps} was, therefore, derived directly from the [mosaic]{.smallcaps} trial for 4 years and was extrapolated to a lifetime horizon. The [os]{.smallcaps} for a full lifespan was derived by extrapolating the [dfs]{.smallcaps} trial data. The method of extrapolation has been described in full detail in Aballéa *et al.* 2007[@b10-conc17-1-17]. In brief, it was assumed that survival of patients in the first 4 years matched the experience of the participants in the [mosaic]{.smallcaps} trial. Survival beyond year 4 and to the end of year 5 was extrapolated using Weibull distributions, and survival beyond year 5 was assumed to match survival in the general population as observed in standard Canadian life tables [@b11-conc17-1-17]. This final assumption required no recurrences of colon cancer beyond 5 years from diagnosis.

### 2.4.2. Quality of Life and Health Utility

The [cua]{.smallcaps} uses the [qaly]{.smallcaps} as a composite measure that combines the length of a patient's life with the quality of life that the patient experiences, where quality of life is measured on a 0 to 1 health utility scale. For example, 5 years at perfect health (utility 1) is worth 5 [qalys]{.smallcaps}; 5 years in poor health (for example, utility 0.5) is worth 2.5 [qalys]{.smallcaps}. To conduct the [cua]{.smallcaps}, estimates of utility were required for disease-free patients with stage [iii]{.smallcaps} colon cancer, and for relapsed patients with stage [iii]{.smallcaps} colon cancer. Disutilities associated with chemotherapy toxicities were also incorporated into the analysis.

#### Utility Associated with "Disease-free" Stage III Colon Cancer

Based on the studies of van den Brink *et al.* [@b12-conc17-1-17] and Ness *et al.* [@b13-conc17-1-17], the utility values for stage [iii]{.smallcaps} colon cancer patients diagnosed with the disease or surviving disease-free were in the range 0.63--0.89. A midpoint value of 0.76 was chosen, meaning that each patient entered the model with a utility of 0.76. For patients who remained "disease-free," annual utility from baseline to year 5 was adjusted to account for declining health as a consequence of aging.

Patients who remained disease-free for 5 years were considered "cured," and their utility was set to that of the general population (specific to the age and sex of the patient).

#### Utility Associated with Relapsed Stage III Colon Cancer

Based again on the studies of van den Brink *et al.* [@b12-conc17-1-17] and Ness *et al.* [@b13-conc17-1-17], utility values for relapse were reported to be in the range 0.24--0.67. We therefore assumed a midpoint value of 0.45 in the base-case analysis for patients with relapsed colon cancer. The patient's annual utility declined from that point forward, until death, to account for aging.

#### Utility Associated with Chemotherapy Toxicities

Finally, utility decrements were incorporated into the model for the proportion of patients experiencing the following types of chemotherapy-related toxicities: grades 3 and 4 neutropenia, grades 2--4 neuropathy, grades 2--4 nausea and vomiting, and grades 2--4 diarrhea. The proportion of patients experiencing these toxicities was derived from the [mosaic]{.smallcaps} study. Estimates of utility associated with chemotherapy-related toxicities in colon cancer were not available in the literature. Accordingly, utility reductions associated with adverse events occurring following chemotherapies for other cancers were extracted from the literature. The utility decrements used in our model were previously detailed by Aballéa *et al.* [@b10-conc17-1-17] in the U.S. cost-effectiveness analysis.

2.5. Costs and Resource Utilization
-----------------------------------

Resource utilization data were derived from the [mosaic]{.smallcaps} trial, supplemented with data from the literature and validated using expert opinion at the Ottawa Hospital Regional Cancer Centre. Unit costs were derived from the London Health Sciences Centre, the Ontario Ministry of Health and Long-Term Care, relevant Web sites such as the [cco]{.smallcaps} site, and the published literature. The types of costs included were study chemotherapy, pre-treatment medications, replacement chemotherapy in the presence of toxicities, serious and non-serious adverse events, disease and toxicity within the trial, and costs of relapses. Costs are reported in 2006 Canadian dollars (CA\$).

### 2.5.1. 2.5.1 Costs of Study Chemotherapy

The costs associated with study chemotherapy included the costs of the 6-month course of treatment with either [folfox]{.smallcaps} or 5[fu]{.smallcaps}/[lv]{.smallcaps}. These costs were calculated using the doses actually administered in the [mosaic]{.smallcaps} trial. The cost for 5[fu]{.smallcaps}/[lv]{.smallcaps} was taken from the [cco]{.smallcaps} Drug Formulary in November 2006[@b8-conc17-1-17], which reported that cost to be CA\$19 per cycle. Oxaliplatin is used at a dose of 85 mg/m^2^, and thus, for a patient with a body surface area of 1.75 m^2^, the cost per cycle of oxaliplatin used in the model was CA\$1487[@b14-conc17-1-17].

In addition to drug acquisition costs, "study chemotherapy costs" included the costs associated with drug administration, including inpatient or outpatient visit, infusion pump, insertion of a peripheral catheter line, pharmacy costs, and nursing costs. The only difference in costs between the two arms was the extra time required to administer the oxaliplatin, and a slightly higher estimate of the pharmacy fee.

### 2.5.2. Costs of Pre-Treatment Medications

In addition to study chemotherapy, patients are often provided with prophylactic medications for chemotherapy-induced side effects. It was assumed that patients received oral ondansetron 8 mg twice daily for 3 days and intravenous dexamethasone (8 mg/mL).

### 2.5.3. Costs of Adverse Events

For each serious adverse event reported in the trial, the corresponding costs (based on codes in the *International Statistical Classification of Diseases and Related Health Problems,* 10th revision [@b15-conc17-1-17]) were collected from a data abstraction through the London Health Sciences Centre. [Table I](#tI-conc17-1-17){ref-type="table"} outlines the serious adverse event costs incorporated into the model. [Table II](#tII-conc17-1-17){ref-type="table"} outlines the costs of non-serious adverse events. The [folfox]{.smallcaps} regimen was associated with higher levels of adverse events than were seen with 5[fu]{.smallcaps}/[lv]{.smallcaps}, including significant differences in neutropenia (with and without fever or infection), thrombocytopenia, paresthesia, nausea and vomiting, diarrhea, and allergic reactions [@b3-conc17-1-17].

### 2.5.4. Costs of Disease and Toxicity Monitoring Within the Trial

The costs of disease monitoring included outpatient visits such as follow-up visits, laboratory tests (for example, platelets, hemoglobin, neutrophils, bilirubin, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, alkaline phosphatase, carcinoembryonic antigens) and radiologic evaluations (for example, chest radiography, abdominal ultrasonography, abdominopelvic computerized tomography) and colonoscopies.

### 2.5.5. Costs of Relapse

The treatment of relapse was assumed to be independent of the study treatment arm. A 2003 study by Maroun *et al.* [@b16-conc17-1-17] estimated the direct health care costs associated with the lifetime management of patients with a diagnosis of colon and rectal cancer in Canada. Of the 487 patients that relapsed in the [mosaic]{.smallcaps} trial, 19% had local recurrences and 81% had metastatic recurrences.

2.6. Sensitivity Analysis
-------------------------

Our base-case analysis compared the [folfox]{.smallcaps} regimen with 5[fu]{.smallcaps}/[lv]{.smallcaps} in stage [iii]{.smallcaps} colon cancer patients over a lifetime horizon. To assess the robustness of our results to changes in input parameters and assumptions, one-way sensitivity analyses were run according to these scenarios:

-   Utility values associated with chemotherapy-related toxicities were varied by plus or minus 20%.

-   Utility values associated with relapse were altered to 0, 0.24, and 0.67 (the base-case assumption was 0.45).

-   Utility values associated with hospitalization were varied from 0% to 100% decrement when the base case was set at a 50% decrement.

A sensitivity analysis was also conducted that considered the full patient population of the [mosaic]{.smallcaps} study, including both stage [ii]{.smallcaps} and stage [iii]{.smallcaps} patients. Finally, a sensitivity analysis was conducted that considered a 4-year time horizon (the duration of follow-up in the [mosaic]{.smallcaps} study).

3.. RESULTS
===========

3.1. Effectiveness
------------------

[Figure 1](#f1-conc17-1-17){ref-type="fig"} summarizes the [dfs]{.smallcaps} and [os]{.smallcaps} differences between the two regimens at 4 years (within-trial), between 4 and 5 years, and extrapolated to 50 years.

During the initial 4-year follow-up, 194 patients treated with [folfox]{.smallcaps} either relapsed or died, compared with 245 patients treated with 5[fu]{.smallcaps}/[lv]{.smallcaps} alone [@b17-conc17-1-17]. The Kaplan--Meier analysis of the [mosaic]{.smallcaps} trial predicted that 69.1% of patients in the oxaliplatin arm would be disease-free at 4 years compared with 60.7% of patients in the 5[fu]{.smallcaps}/[lv]{.smallcaps} arm (log-rank test: *p* = 0.002). Within-trial [dfs]{.smallcaps} and [os]{.smallcaps} translated into gains, with discounting, of 0.192 [dfys]{.smallcaps} and 0.054 [lys]{.smallcaps} for [folfox]{.smallcaps}-treated patients, as shown in [Table III](#tIII-conc17-1-17){ref-type="table"}.

By using a Weibull extrapolation to fit the model to the tail end of the within-trial survival curve, [dfs]{.smallcaps} and [os]{.smallcaps} were extrapolated from 4 years to 5 years (60 months). The gains observed between the 4-year and 5-year time periods were added to the improvements observed up to 4 years, resulting in differences in favour of oxaliplatin of 0.262 and 0.085 in [dfys]{.smallcaps} and [lys]{.smallcaps} respectively.

Using Canadian life tables to extrapolate the [os]{.smallcaps} and [dfs]{.smallcaps} curves, with discounting, total accruals for [folfox]{.smallcaps}-treated patients were 1.08 and 0.653 in [dfys]{.smallcaps} and [lys]{.smallcaps} respectively.

3.2. Cost Outcomes
------------------

As illustrated in [Table IV](#tIV-conc17-1-17){ref-type="table"}, the largest contributor to total cost for each treatment arm was chemotherapy, at CA\$15,665 for [folfox]{.smallcaps} and CA\$1757 for 5[fu]{.smallcaps}/[lv]{.smallcaps} (incremental difference: CA\$13,908). The cost of the chemotherapy was based on the actual chemotherapy administered in the [mosaic]{.smallcaps} trial. The planned 12 cycles of adjuvant therapy were received by 86% of patients in the 5[fu]{.smallcaps}/[lv]{.smallcaps} group and 75% of patients in the [folfox]{.smallcaps} group. The median relative dose intensity of 5[fu]{.smallcaps} received was 84% for the [folfox]{.smallcaps} group and 98% for the 5[fu]{.smallcaps}/[lv]{.smallcaps} group. Costs associated with relapse on treatment and relapse during follow-up were lower with the [folfox]{.smallcaps} regimen. However, higher drug acquisition costs for [folfox]{.smallcaps} and costs associated with treating chemotherapy-related toxicities were major cost drivers, resulting in an incremental cost of CA\$15,409 for [folfox]{.smallcaps} patients over a lifetime horizon.

3.3. Cost-Effectiveness
-----------------------

The base-case analysis demonstrated that adjuvant chemotherapy was more effective with [folfox]{.smallcaps} than with 5[fu]{.smallcaps}/[lv]{.smallcaps}, but it was also more costly. The [lys]{.smallcaps} and [qalys]{.smallcaps} were higher because of greater [dfs]{.smallcaps} and [os]{.smallcaps} in the [folfox]{.smallcaps} arm as compared with the arm using 5[fu]{.smallcaps}/[lv]{.smallcaps} alone. [Table V](#tV-conc17-1-17){ref-type="table"} shows cost per [ly]{.smallcaps} saved and cost per [qaly]{.smallcaps} gained for [folfox]{.smallcaps} as compared with 5[fu]{.smallcaps}/[lv]{.smallcaps}.

3.4. Sensitivity Analyses
-------------------------

A number of sensitivity analyses were conducted to evaluate the robustness of the base-case results. Most of the sensitivity analyses had little effect on the results. Interestingly, including stage [ii]{.smallcaps} patients from the [mosaic]{.smallcaps} trial still resulted in a cost per [qaly]{.smallcaps} of CA\$33,534 over a lifetime horizon. However, as expected, limiting the analysis to 4 years resulted in a cost-effectiveness ratio for stage [iii]{.smallcaps} patients of more than CA\$200,000 per [qaly]{.smallcaps} gained.

There are concerns with the external validity of the utility estimates, but the estimates used in the base-case analysis represent the best available data. Uncertainty in connection with the utility decrement associated with relapse had a large impact on the results of the within-trial analysis (for example, the 4-year time horizon); however, the effect of this parameter on the long-term results is modest. The incremental cost-effectiveness ratio ([icer]{.smallcaps}) was CA\$30,402 when no utility decrement associated with relapse was assumed; that figure decreased to CA\$21,138 when a 0.24 utility for a relapse was estimated.

4.. DISCUSSION
==============

After a complete surgical resection (undertaken with curative intent), patients with stage [iii]{.smallcaps} colon cancer have a 50%--60% chance of developing recurrent disease [@b18-conc17-1-17]. New therapies that improve [dfs]{.smallcaps} in these patients, such as [folfox]{.smallcaps}, are thus vital. Based on the [mosaic]{.smallcaps} study, we therefore analyzed the cost-effectiveness of the [folfox]{.smallcaps} regimen in stage [iii]{.smallcaps} patients.

Cost-effectiveness analysis using [qalys]{.smallcaps} permits funding agencies to consider the value of alternative therapies, taking into account costs in addition to both quantity and quality of survival. Although patients on [folfox]{.smallcaps} had a greater incidence of toxicities than did those on 5[fu]{.smallcaps}/[lv]{.smallcaps}, the negative effect of the toxicities on [qalys]{.smallcaps} was outweighed by the [qalys]{.smallcaps} gained from improved survival with [folfox]{.smallcaps}. The gain in [qalys]{.smallcaps} was obtained at a reasonable cost-per-[qaly]{.smallcaps} ratio of CA\$24,104.

The results from our evaluation appear to be very similar to the U.S. cost-effectiveness results presented by Aballéa *et al.* [@b10-conc17-1-17] After discounting costs and outcomes at 3% per annum, the U.S. evaluation reported an [icer]{.smallcaps} of US\$20,600 per [ly]{.smallcaps} gained and US\$22,800 per [qaly]{.smallcaps} gained. Likewise, the analysis submitted to the National Institute for Clinical Excellence by Sanofi--Aventis U.K. presented a cost--utility ratio of £4805 per [qaly]{.smallcaps} gained over a lifetime horizon [@b18-conc17-1-17]. Comparing the [qaly]{.smallcaps} estimates, the Canadian and the U.K. models were very similar, with incremental differences between the two arms of 0.68 in the U.K. model and 0.639 in the Canadian model. The differences resulted from the use of different discount rates in the two analyses and also from some updated utility estimates that were available for the Canadian analysis. The results were higher in Canada and the United States as compared with the United Kingdom because of the relative difference in the price of oxaliplatin as compared with 5[fu]{.smallcaps}/[lv]{.smallcaps} between the countries. In the same disease setting, the estimated cost per [ly]{.smallcaps} gained for capecitabine as compared with 5[fu]{.smallcaps}/[lv]{.smallcaps} was £3899 (after discounting at 3.5% for costs and outcomes) [@b19-conc17-1-17].

A limitation of the [mosaic]{.smallcaps} trial data in informing this economic analysis is that [mosaic]{.smallcaps} was not designed for such purposes and was not powered to detect a significant difference in [os]{.smallcaps}. The [dfs]{.smallcaps} data from the [mosaic]{.smallcaps} trial was used to calculate recurrence rates---and ultimately to estimate survival. Thus, the value of [dfs]{.smallcaps} as a predictor of longer-term [os]{.smallcaps} is key to this analysis. The literature suggests that this predictive power holds, because a meta-analysis of clinical trials on adjuvant colon cancer has shown that [dfs]{.smallcaps} at 3 years is a strong predictor of [os]{.smallcaps} at 5 years [@b20-conc17-1-17]. Moreover, since the time of the original evaluation, the [mosaic]{.smallcaps} trial investigators have published 6-year [os]{.smallcaps} data [@b5-conc17-1-17]. We were thus able to test the predictive validity of the model at the 6-year time point. For stage [iii]{.smallcaps} patients, the [os]{.smallcaps} reported was 72.9% for [folfox]{.smallcaps} and 68.7% for 5[fu]{.smallcaps}/[lv]{.smallcaps} [@b5-conc17-1-17]. The model predicted 71.4% for [folfox]{.smallcaps} and 67.1% for 5[fu]{.smallcaps}/[lv]{.smallcaps}. These results illustrate that, at the 6-year point, the model was within 1.5% of the actual [os]{.smallcaps} observed in the trial.

Another limitation is that many of the resource utilization estimates were informed from the trial. Should some of the resource utilization have been protocol-driven, then resource utilization in our analysis may have been overestimated. In an attempt to correct for this possibility, we held consultations with clinicians to ensure that assumptions in our analysis reflected current practice.

Finally, the availability of relevant utility values for the calculation of [qalys]{.smallcaps} was limited. We believe that the evaluation presented here used the best available data; the results of the sensitivity analysis suggest that the effect of this parameter on long-term results is modest.

Based in part on the information presented in the present economic evaluation, the province of Ontario recommended that oxaliplatin in combination with 5[fu]{.smallcaps}/[lv]{.smallcaps} ([folfox]{.smallcaps}) be funded for the adjuvant treatment of colon cancer. Based on the biologic similarities between colon and rectal cancer, the provinces of Ontario and British Columbia have both extended their funding to include rectal cancer. Within the clinical community, the strong evidence put forward by the Intergroup N9741 study [@b21-conc17-1-17] and by the [mosaic]{.smallcaps} trial have led to oxaliplatin being part of the standard of care of colorectal cancer in Canada.

5.. CONCLUSIONS
===============

The analysis presented here demonstrates that adding oxaliplatin to 5[fu]{.smallcaps}/[lv]{.smallcaps} in the adjuvant setting in patients with stage [iii]{.smallcaps} colon cancer represents a cost-effective use of resources.

Cornerstone Research Group Inc. is an independent research organization and was contracted by Sanofi--Aventis Canada Inc. to conduct the health economic evaluation presented here. The original cost-effectiveness analysis model was developed by i3 Innovus and later adapted for Canada by Cornerstone. Sanofi--Aventis Canada Inc. was solely responsible for the funding of all components of this analysis.

Portions of this analysis were presented in a poster at the National Oncology Pharmacy Symposium; Halifax, Nova Scotia; October 26--28, 2007 \[Attard C, Maroun J, Alloul K, Grima D, Bernard L. Canadian cost-effectiveness analysis of oxaliplatin (Eloxatin) in the adjuvant treatment of stage [iii]{.smallcaps} colon cancer\].

![Within-trial and extrapolated survival differences over time. OS = overall survival; DFS=disease-free survival; FOLFOX = folinic acid, 5-fluorouracil, oxaliplatin; 5FU/LV = leucovorin/5-fluorouracil](conc17-1-17f1){#f1-conc17-1-17}

###### 

Costs of serious adverse events

  [icd]{.smallcaps}-10 code   Description                 Length of stay (days)   Cost per case (2006 CA\$)
  --------------------------- --------------------------- ----------------------- ---------------------------
  R50                         Fever                       4.02                    4,304
  T88.7                       Allergic reaction           1                       1,438
  K52.9                       Diarrhea                    7.95                    8,355
  J13 J18.9                   Pneumonia                   7.97                    7,581
  D70                         Neutropenic sepsis          6.26                    7,285
  R11.1, R11.2, R11.3         Nausea and vomiting         3.64                    2,969
  I80.2                       Deep leg thrombophlebitis   9.00                    6,754
  078                         Pulmonary embolism          6.30                    6,676
  R10                         Abdominal pain              2.6                     2,390
  K56.6                       Intestinal obstruction      9.7                     11,529
  T80                         Injection site reaction     3.0                     3,305

[icd]{.smallcaps}-10 = *International Statistical Classification of Diseases and Related Health Problems,* 10th revision [@b16-conc17-1-17].

###### 

Costs of non-serious adverse events

  Description           Treatment assumption                                                                               Cost per case (2006 CA\$)
  --------------------- -------------------------------------------------------------------------------------------------- ---------------------------
  Nausea and vomiting                                                                                                      10.76/episode
   Grade 2              Prochlorperazine (10 mg) in combination with oral dexamethasone (4 mg), 4 times daily for 3 days   
   Grades 3 and 4       Intravenous prochlorperazine and oral dexamethasone (8 mg) for 3 days                              13.12/episode
  Neutropenia                                                                                                              
   Grade 2              No treatment                                                                                       0
   Grades 3 and 4       Admitted to hospital                                                                               5197
  Diarrhea              Loperamide (16 mg daily for 12 days); stool culture and test for *Clostridium difficile*           25.75

###### 

Incremental health outcomes, discounted by 5%

  Time horizon   Outcome               [folfox]{.smallcaps}   5[fu]{.smallcaps}/[lv]{.smallcaps}   Difference
  -------------- --------------------- ---------------------- ------------------------------------ ------------
  4 Years        [dfys]{.smallcaps}    3.042                  2.850                                0.192
                 [lys]{.smallcaps}     3.372                  3.318                                0.054
                 [qalys]{.smallcaps}   2.440                  2.373                                0.067
  5 Years        [dfys]{.smallcaps}    3.605                  3.343                                0.262
                 [lys]{.smallcaps}     4.003                  3.917                                0.085
                 [qalys]{.smallcaps}   NA                     NA                                   NA
  50 Years       [dfys]{.smallcaps}    9.861                  8.781                                1.080
                 [lys]{.smallcaps}     10.418                 9.765                                0.653
                 [qalys]{.smallcaps}   8.048                  7.409                                0.639

[folfox]{.smallcaps} = folinic acid, 5-fluorouracil, oxaliplatin; 5[fu]{.smallcaps} = 5-fluorouracil; [lv]{.smallcaps} = leucovorin; [dfys]{.smallcaps} = disease-free years; [lys]{.smallcaps} = life-years; [qalys]{.smallcaps} = quality-adjusted life-years; [na]{.smallcaps} = not available.

###### 

Disaggregated within-trial and beyond-trial costs in 2006 Canadian dollars, discounted by 5%

  Cost category             Costs             
  ------------------------- -------- -------- --------
  Within-trial costs                          
   Study chemotherapy       15,665   1,757    13,908
   Outpatient visits        638      661      −23
   Lab tests                236      244      −8
   Radiologic evaluations   1,837    1,889    −52
   Neutropenia              2,553    226      2,328
   Neuropathy               0        0        0
   Diarrhea                 13       11       2
   Nausea and vomiting      10       3        6
   Serious adverse events   1,677    1,041    636
   Relapse treatment        3,074    4,175    −1,100
   Relapse follow-up        429      618      −189
   TOTAL                    26,133   10,623   15,509
  Beyond-trial costs                          
   Relapse                  200      297      −97
   Follow-up                1,106    998      108
   Other                    287      398      −111
  LIFETIME TOTAL            27,726   12,317   15,409

[folfox]{.smallcaps} = folinic acid, 5-fluorouracil, oxaliplatin; 5[fu]{.smallcaps} = 5-fluorouracil; [lv]{.smallcaps} = leucovorin.

###### 

Cost--utility analysis

                                        Costs (2006 CA\$)   [dfys]{.smallcaps}   [lys]{.smallcaps}   [qalys]{.smallcaps}
  ------------------------------------- ------------------- -------------------- ------------------- ---------------------
  Regimen                                                                                            
   [folfox]{.smallcaps}                 27,726              9.861                10.418              8.048
   5[fu]{.smallcaps}/[lv]{.smallcaps}   12,317              8.781                9.765               7.409
  Incremental                           15,409              1.080                0.653               0.639
  [icer]{.smallcaps}^a^                                     14,266               23,598              24,104

[dfy]{.smallcaps} = disease-free years; [ly]{.smallcaps} = life-years; [qaly]{.smallcaps} = quality-adjusted life-years; [folfox]{.smallcaps} = folinic acid, 5-fluorouracil, oxaliplatin; 5[fu]{.smallcaps} = 5-fluorouracil; [lv]{.smallcaps} = leucovorin; [icer]{.smallcaps} = incremental costeffectiveness ratio.
